ClinicalTrials.gg
CompletedNCT05239221Updated Sep 8, 2025Results posted

AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

A Phase 1/2 interventional study of AZP-3601 and Placebo in Chronic Hypoparathyroidism, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Sep 2020, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP)

The protocol includes 3 parts:

  • Part A: first-in-human single ascending dose (SAD) study in healthy volunteers
  • Part B: multiple ascending dose (MAD) study with 2 weeks of treatment in healthy volunteers
  • Part C: open-label MAD study with a total treatment duration of 3 months in patients with cHP.
02

Conditions studied

  • Chronic Hypoparathyroidism

Browse trials for

03

In context

Hypoparathyroidism

128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.

This study's enrollment of 132 is above the median of 50 across 77 interventional studies indexed under Hypoparathyroidism.

Browse Hypoparathyroidism studies →

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main inclusion criteria

  • Part A: healthy male volunteers aged 18 to 60 years old inclusive with a of 19 to 28 kg/m2
  • Part B: healthy male and female volunteers (non-child bearing potential) aged 18 to 60 years inclusive with a Body mass index of 19 to 28 kg/m2
  • Part C:

    1. Male and female patients aged 18 to 75 years inclusive
    2. History of cHP for ≥12 months at the time of screening with documentation of two measurements of serum calcium and parathyroid hormone (PTH).
    3. Requirement for therapy with calcitriol ≥0.25 μg per day or alphacalcidol ≥0.50 μg per day (both are active vitamin D supplements), and requirement for supplemental oral calcium treatment ≥1000 mg per day over and above normal dietary calcium intake at baseline assessments.

Main exclusion criteria

  • Parts A and B:

    1. abnormal lab values, as judged by the investigator
    2. Using tobacco products with 3 months prior to first drug administration
    3. History of alcohol abuse or drug addiction
  • Part C:

    1. Known history of autosomal-dominant hypocalcemia (ADH resulting from gain-of-function calcium-sensing receptor [CaSR] or GNA11 mutations) or pseudohypoparathyroidism (impaired responsiveness to PTH)
    2. Any current disease that might affect calcium metabolism or calcium phosphate homeostasis other than HP
    3. Use of medications such as loop and thiazide diuretics, raloxifene hydrochloride, lithium, methotrexate, cardiac glycosides (e.g., digoxin or digitoxin) or systemic within 4 weeks prior to start of treatment.
    4. Previous treatment with PTH-like drugs, including PTH(1-84), PTH(1-34), or abaloparatide, within 3 months prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    AZP-3601

    subcutaneous (sc) administration once daily

    Drug: AZP-3601

  • Placebo comparator
    Placebo (Parts A and B)

    subcutaneous (sc) administration once daily

    Drug: Placebo

Interventions

  • DrugAZP-3601

    Lyophilized powder of AZP-3601 to be reconstituted with water for injection before injection

    Also known as: eneboparatide

  • DrugPlacebo

    Saline solution visually matching active medication

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (TEAEs)

    Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25).

    Time frame: Up to 2 weeks in Part A and Part B, and up to 3 months in Part C

Secondary outcomes

  1. Observed Maximum Concentration (Cmax) - Part A

    Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part A

    Time frame: 24 hours

  2. Observed Maximum Concentration (Cmax) - Part B

    Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part B

    Time frame: Day 1, Day 14

  3. Observed Maximum Concentration (Cmax) - Part C

    Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part C.

    Time frame: Day 1, Day 14, Day 28, Day 84

  4. Area Under the Plasma-drug Concentration Time Curve (AUC) - Part A

    Area under the plasma-drug concentration time curve (AUC) (pg\*h/mL) in Part A

    Time frame: 24 hours

  5. Area Under the Plasma-drug Concentration Time Curve (AUC) - Part B

    Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part B

    Time frame: Day 1, Day 14

  6. Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C

    Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part C.

    Time frame: Day 1, Day 14, Day 28, Day 84

  7. Calcium Corrected for Albumin - Part A

    Levels of calcium corrected for albumin (mg/dL) in Part A

    Time frame: 24 hours

  8. Calcium Corrected for Albumin - Part B

    Levels of calcium corrected for albumin (mg/dL) in Part B

    Time frame: 24 hours, Day 14

  9. Calcium Corrected for Albumin - Part C

    Levels of calcium corrected for albumin (mg/dL) in Part C.

    Time frame: Day 1, Day 14, Day 28 and Day 84

  10. Serum Phosphate - Part A

    Serum phosphate levels (mg/dL) in Part A

    Time frame: 24 hours

  11. Serum Phosphate - Part B

    Serum phosphate levels (mg/dL) in Part B

    Time frame: Day 1, Day 14

  12. Serum Phosphate - Part C

    Serum phosphate levels (mg/dL) in Part C.

    Time frame: Day 1 (H0), Day 14 (H2), Day 28 (H2) and Day 84 (H2)

  13. Daily Dose of Oral Calcium and Active Vitamin D - Part C

    Daily dose of oral calcium and active vitamin D for patients treated in Part C.

    Time frame: Day 28 and Day 43

Other outcomes

  1. Calcium Excretion Rate 24h- Part C

    24 hour calcium excretion rate (mg/24h) in Part C.

    Time frame: Day 1, Day 14, Day 28 and Day 84

07

Results

Posted Jan 31, 2024

Participant flow

Participant flow — Overall Study
MilestonePart A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Started366666613881088101216
Completed36666651388878101215
Not completed0000001000210001
Withdrew: Adverse event0000001000110000
Withdrew: Withdrawal by subject0000000000100001

Outcome measures

PrimaryTreatment Emergent Adverse Events (TEAEs)

Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25).

Time frame:
Up to 2 weeks in Part A and Part B, and up to 3 months in Part C
Reported as:
Count of participants · Participants
Treatment Emergent Adverse Events (TEAEs)
ParticipantsPart A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Treatment Emergent Adverse Events (TEAEs)235136686710879712
SecondaryObserved Maximum Concentration (Cmax) - Part A

Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part A

Time frame:
24 hours
Reported as:
Mean · pg/mL
Observed Maximum Concentration (Cmax) - Part A
pg/mLPart A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)
Observed Maximum Concentration (Cmax) - Part A6.82 ± 2.1911.4 ± 4.3224.1 ± 8.1826.3 ± 4.7928.5 ± 10.857.4 ± 28.737.5 ± 11.6
SecondaryObserved Maximum Concentration (Cmax) - Part B

Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part B

Time frame:
Day 1, Day 14
Reported as:
Mean · pg/mL
Observed Maximum Concentration (Cmax) - Part B
pg/mLPart B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)
Day 120.6 ± 3.4319.6 ± 5.6823.8 ± 8.9742.9 ± 30.3124 ± 105
Day 1418.4 ± 5.3718.3 ± 6.7823.6 ± 5.5044.9 ± 17.963.5 ± 28.3
SecondaryObserved Maximum Concentration (Cmax) - Part C

Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part C.

Time frame:
Day 1, Day 14, Day 28, Day 84
Reported as:
Mean · pg/mL
Observed Maximum Concentration (Cmax) - Part C
pg/mLPart C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Day 121.3 ± 9.2011.9 ± 7.82
Day 1422.3 ± 11.710.4 ± 7.73
Day 2818.4 ± 7.4221.5 ± 17.9
Day 84—89.9 ± 63.9
SecondaryArea Under the Plasma-drug Concentration Time Curve (AUC) - Part A

Area under the plasma-drug concentration time curve (AUC) (pg\*h/mL) in Part A

Time frame:
24 hours
Reported as:
Mean · pg*h/mL
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part A
pg*h/mLPart A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part A0.399 ± 0.0325.20 ± 3.389.55 ± 4.1210.4 ± 13.416.8 ± 14.726.1 ± 16.431.7 ± 12.5
SecondaryArea Under the Plasma-drug Concentration Time Curve (AUC) - Part B

Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part B

Time frame:
Day 1, Day 14
Reported as:
Mean · pg*h/mL
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part B
pg*h/mLPart B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)
Day 13.26 ± 3.207.69 ± 5.5215.8 ± 11.543.3 ± 18.164.2 ± 56.1
Day 142.02 ± 2.414.63 ± 3.2912.5 ± 4.7558.8 ± 30.351.9 ± 51.6
SecondaryArea Under the Plasma-drug Concentration Time Curve (AUC) - Part C

Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part C.

Time frame:
Day 1, Day 14, Day 28, Day 84
Reported as:
Mean · pg*h/mL
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C
pg*h/mLPart C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Day 111.9 ± 9.534.90 ± 4.87
Day 1416.1 ± 14.03.99 ± 4.22
Day 2812.7 ± 7.5811.8 ± 11.1
Day 84—116 ± 111
SecondaryCalcium Corrected for Albumin - Part A

Levels of calcium corrected for albumin (mg/dL) in Part A

Time frame:
24 hours
Reported as:
Mean · mg/dL
Calcium Corrected for Albumin - Part A
mg/dLPart A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)
Calcium Corrected for Albumin - Part A9.700 ± 0.08009.375 ± 0.62159.688 ± 0.34489.782 ± 0.430310.065 ± 0.293410.293 ± 0.525810.195 ± 0.26019.634 ± 0.3030
SecondaryCalcium Corrected for Albumin - Part B

Levels of calcium corrected for albumin (mg/dL) in Part B

Time frame:
24 hours, Day 14
Reported as:
Mean · mg/dL
Calcium Corrected for Albumin - Part B
mg/dLPart B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)
24 hours9.818 ± 0.32839.661 ± 0.349210.121 ± 0.432010.01 ± 0.3010.01 ± 0.419.68 ± 0.21
Day 149.586 ± 0.31739.650 ± 0.208110.055 ± 0.591610.06 ± 0.5910.94 ± 0.979.79 ± 0.24
SecondaryCalcium Corrected for Albumin - Part C

Levels of calcium corrected for albumin (mg/dL) in Part C.

Time frame:
Day 1, Day 14, Day 28 and Day 84
Reported as:
Mean · mg/dL
Calcium Corrected for Albumin - Part C
mg/dLPart C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Day 1 (hour 0)8.44 ± 0.4208.61 ± 0.552
Day 148.48 ± 0.5378.38 ± 0.726
Day 288.64 ± 0.4918.537 ± 0.697
Day 847.95 ± 0.8178.73 ± 0.878
SecondarySerum Phosphate - Part A

Serum phosphate levels (mg/dL) in Part A

Time frame:
24 hours
Reported as:
Mean · mg/dL
Serum Phosphate - Part A
mg/dLPart A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)
Serum Phosphate - Part A3.353 ± 0.66462.882 ± 0.38843.840 ± 0.51353.287 ± 0.50213.908 ± 0.50513.673 ± 0.49753.417 ± 0.41333.641 ± 0.3637
SecondarySerum Phosphate - Part B

Serum phosphate levels (mg/dL) in Part B

Time frame:
Day 1, Day 14
Reported as:
Mean · mg/dL
Serum Phosphate - Part B
mg/dLPart B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)
Day 13.616 ± 0.19193.751 ± 0.32293.824 ± 0.54213.518 ± 0.33323.398 ± 0.39653.65 ± 0.58
Day 143.601 ± 0.22993.850 ± 0.33973.603 ± 0.47383.727 ± 0.39703.553 ± 0.60373.74 ± 0.40
SecondarySerum Phosphate - Part C

Serum phosphate levels (mg/dL) in Part C.

Time frame:
Day 1 (H0), Day 14 (H2), Day 28 (H2) and Day 84 (H2)
Reported as:
Mean · mg/dL
Serum Phosphate - Part C
mg/dLPart C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Day 14.12 ± 0.7984.53 ± 0.780
Day 143.43 ± 0.7423.95 ± 0.849
Day 283.50 ± 0.8433.82 ± 0.868
Day 843.60 ± 0.5893.80 ± 6.83
SecondaryDaily Dose of Oral Calcium and Active Vitamin D - Part C

Daily dose of oral calcium and active vitamin D for patients treated in Part C.

Time frame:
Day 28 and Day 43
Reported as:
Count of participants · Participants
Daily Dose of Oral Calcium and Active Vitamin D - Part C
ParticipantsPart C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Number of patients taking =< 500 mg/day of calcium on Day 28912
Number of patients taking =< 500 mg/day of calcium on Day 84813
Number of patients taking no vitamin D on Day 281012
Number of patients taking no vitamin D on Day 84913
Other pre-specifiedCalcium Excretion Rate 24h- Part C

24 hour calcium excretion rate (mg/24h) in Part C.

Time frame:
Day 1, Day 14, Day 28 and Day 84
Reported as:
Mean · mg/24h
Calcium Excretion Rate 24h- Part C
mg/24hPart C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
Day 1328.72 ± 130.950330.73 ± 189.154
Day 14224.83 ± 108.570188.41 ± 100.054
Day 28155.06 ± 61.705166.43 ± 96.637
Day 84115.70 ± 37.929145.15 ± 113.563

Adverse events

Collected over Up to 2 weeks (Part A and Part B) and up to 3 months (Part C). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A (Cohort A1, 5 ug Dose)0/3 (0%)0/3 (0%)2/3 (66.7%)
Part A (Cohort A2, 10 ug Dose)0/6 (0%)0/6 (0%)3/6 (50%)
Part A (Cohort A3, 20 ug Dose)0/6 (0%)0/6 (0%)5/6 (83.3%)
Part A (Cohort A4, 40 ug Dose)0/6 (0%)0/6 (0%)1/6 (16.7%)
Part A (Cohort A5, 60 ug Dose)0/6 (0%)0/6 (0%)3/6 (50%)
Part A (Cohort A6, 120 ug Dose)0/6 (0%)0/6 (0%)6/6 (100%)
Part A (Cohort A7, 90 ug Dose)0/6 (0%)0/6 (0%)6/6 (100%)
Part A (Placebo)0/13 (0%)0/13 (0%)8/13 (61.5%)
Part B (Cohort B1, 10 ug Doses)0/8 (0%)0/8 (0%)6/8 (75%)
Part B (Cohort B2, 20 ug Doses)0/8 (0%)0/8 (0%)7/8 (87.5%)
Part B (Cohort B3, 40 ug Doses)0/10 (0%)0/10 (0%)10/10 (100%)
Part B (Cohort B4, 60 ug Doses)0/8 (0%)0/8 (0%)8/8 (100%)
Part B (Cohort B5, 80 ug Doses)0/8 (0%)0/8 (0%)7/8 (87.5%)
Part B (Placebo)0/10 (0%)0/10 (0%)9/10 (90%)
Part C (Cohort C1, Starting Dose of 20 ug/Day)0/12 (0%)0/12 (0%)7/12 (58.3%)
Part C (Cohort C2, Starting Dose of 10 ug/Day)0/16 (0%)0/16 (0%)12/16 (75%)
Most frequent other events
Showing 10 of 93
Most frequent other events
EventPart A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)
NauseaGastrointestinal disorders0/30/60/60/61/64/63/61/130/82/81/105/84/83/101/120/16
SomnolenceNervous system disorders0/30/60/60/60/64/61/60/130/80/83/103/82/81/100/120/16
Injection Site HematomaGeneral disorders0/30/60/60/60/60/60/60/132/83/85/103/83/83/101/122/16
Decreased appetiteMetabolism and nutrition disorders0/30/61/60/60/63/62/60/130/80/81/102/80/80/100/120/16
headacheNervous system disorders1/31/61/60/60/63/62/60/130/81/82/104/81/83/102/124/16
Injection Site ErythemaGeneral disorders0/30/60/60/60/60/62/61/130/81/84/103/82/81/101/125/16
MyalgiaMusculoskeletal and connective tissue disorders0/30/60/60/61/60/60/60/131/80/84/100/80/80/100/120/16
VomitingGastrointestinal disorders0/30/60/60/60/60/61/60/130/80/80/103/81/80/100/120/16
Vessel puncture site hematomaGeneral disorders0/30/60/60/60/60/60/60/130/83/80/101/81/82/100/120/16
Injection Site PainGeneral disorders0/30/61/60/60/60/62/64/131/80/80/102/81/81/101/120/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)Total
Mean29.3 (28 to 30)38.8 (20 to 59)23.7 (19 to 33)30.0 (20 to 60)26.3 (20 to 50)21.0 (18 to 24)35.3 (23 to 58)29.2 (18 to 57)38.3 (19 to 59)42.9 (28 to 60)39.7 (19 to 59)30.1 (19 to 43)33.3 (20 to 48)32.0 (22 to 57)62.7 (44 to 72)54.0 (26 to 72)37.9 (18 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Part A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)Total
Female0000000002100191225
Male36666661386988934107
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)Total
Hispanic or Latino00000101001123009
Not Hispanic or Latino3666656128897671215122
Unknown or Not Reported00000000000000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)Total
American Indian or Alaska Native00100000000001002
Asian00000000020100003
Native Hawaiian or Other Pacific Islander00000000000000000
Black or African American00000000000030003
White35555561085107371216112
More than one race010111030100220012
Unknown or Not Reported00000000000000000
Region of Enrollment
Region of Enrollment(participants)Part A (Cohort A1, 5 ug Dose)Part A (Cohort A2, 10 ug Dose)Part A (Cohort A3, 20 ug Dose)Part A (Cohort A4, 40 ug Dose)Part A (Cohort A5, 60 ug Dose)Part A (Cohort A6, 120 ug Dose)Part A (Cohort A7, 90 ug Dose)Part A (Placebo)Part B (Cohort B1, 10 ug Doses)Part B (Cohort B2, 20 ug Doses)Part B (Cohort B3, 40 ug Doses)Part B (Cohort B4, 60 ug Doses)Part B (Cohort B5, 80 ug Doses)Part B (Placebo)Part C (Cohort C1, Starting Dose of 20 ug/Day)Part C (Cohort C2, Starting Dose of 10 ug/Day)Total
Hungary000000000000009615
Spain00000000000000347
France00000000000000066
Netherlands3666666138810881000104
08

Study locations

2 sites
  • Amolyt Pharma Investigational Site Hungary
    Budapest, Hungary
  • PRA-EDS
    Groningen, 9728, Netherlands
09

References and documents

Publications

  • Ovize M, Allas S, Culler MD, Milano S, Ouldrouis T, Sumeray M, van de Wetering de Rooij J, Mannstadt M. Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist. Endocr Connect. 2025 Jun 19;14(6):e240464. doi: 10.1530/EC-24-0464. Print 2025 Jun 1. PubMed 40423237 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Aug 2022, 23 months.

Results were first posted in Jan 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2022
First posted
Feb 14, 2022
StartActual
Sep 7, 2020
Primary completionActual
Aug 23, 2022
CompletionActual
Aug 23, 2022
Results first posted
Jan 31, 2024
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05239221
Collaborators
Amolyt Pharma
Responsible party
Sponsor
First posted
Feb 14, 2022
Start date
Sep 7, 2020
Primary completion
Aug 23, 2022
Completion
Aug 23, 2022
Results posted
Jan 31, 2024
Last update
Sep 8, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion